Recursion Pharmaceuticals, Inc. (RXRX)
Largest Insider Buys in Sector
RXRX Stock Price History Chart
RXRX Stock Performance
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Insider Activity of Recursion Pharmaceuticals, Inc.
Over the last 12 months, insiders at Recursion Pharmaceuticals, Inc. have bought $0 and sold $21.41M worth of Recursion Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Recursion Pharmaceuticals, Inc. have bought $66.24M and sold $19.8M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 66,822 shares for transaction amount of $522,354 was made by Mubadala Investment Co PJSC (10 percent owner) on 2023‑03‑02.
List of Insider Buy and Sell Transactions, Recursion Pharmaceuticals, Inc.
| 2024-06-14 | Sale | Secora Michael | Chief Financial Officer | 15,000 0.007% | $9.27 | $139,082 | +1.03% | |
| 2024-06-13 | Sale | Secora Michael | Chief Financial Officer | 15,000 0.0071% | $9.32 | $139,799 | -1.06% | |
| 2024-06-11 | Sale | Borgeson Blake | director | 11,447 0.0049% | $8.45 | $96,763 | +8.86% | |
| 2024-06-06 | Sale | Gibson Christopher | Chief Executive Officer | 50,000 0.0217% | $9.00 | $450,000 | +3.00% | |
| 2024-06-05 | Sale | Gibson Christopher | Chief Executive Officer | 50,000 0.0201% | $8.42 | $421,000 | +1.87% | |
| 2024-05-30 | Sale | Marriott Tina | President and COO | 3,000 0.0013% | $8.78 | $26,325 | +2.48% | |
| 2024-05-28 | Sale | Borgeson Blake | director | 11,447 0.0051% | $9.17 | $104,943 | +0.22% | |
| 2024-05-14 | Sale | Borgeson Blake | director | 20,054 0.0088% | $10.12 | $202,934 | -8.91% | |
| 2024-05-02 | Sale | Gibson Christopher | Chief Executive Officer | 21,296 0.0089% | $8.47 | $180,377 | +3.19% | |
| 2024-05-01 | Sale | Gibson Christopher | Chief Executive Officer | 50,000 0.0201% | $7.73 | $386,500 | +8.40% | |
| 2024-04-30 | Sale | Borgeson Blake | director | 11,447 0.0051% | $7.95 | $90,964 | +15.35% | |
| 2024-04-25 | Sale | Marriott Tina | President and COO | 3,000 0.0014% | $7.67 | $23,021 | +14.67% | |
| 2024-04-17 | Sale | Secora Michael | Chief Financial Officer | 23,124 0.0109% | $7.58 | $175,349 | +18.47% | |
| 2024-04-16 | Sale | Borgeson Blake | director | 11,447 0.0054% | $7.66 | $87,725 | +17.00% | |
| 2024-04-16 | Sale | Secora Michael | Chief Financial Officer | 25,000 0.0117% | $7.67 | $191,658 | +17.00% | |
| 2024-04-04 | Sale | Gibson Christopher | Chief Executive Officer | 65,000 0.0311% | $9.02 | $586,300 | +1.32% | |
| 2024-04-03 | Sale | Gibson Christopher | Chief Executive Officer | 65,000 0.0298% | $8.84 | $574,600 | -1.01% | |
| 2024-04-02 | Sale | Borgeson Blake | director | 11,447 0.0053% | $8.82 | $100,942 | +0.86% | |
| 2024-03-28 | Sale | Gibson Christopher | Chief Executive Officer | 65,000 0.0305% | $10.10 | $656,500 | -11.28% | |
| 2024-03-21 | Sale | Marriott Tina | President and COO | 8,000 0.0037% | $10.75 | $85,980 | -16.71% |
Insider Historical Profitability
| Borgeson Blake | director | 7188563 3.3874% | $8.76 | 0 | 49 | |
| Secora Michael | Chief Financial Officer | 1267843 0.4544% | $8.76 | 0 | 24 | |
| Gibson Christopher | Chief Executive Officer | 708738 0.3589% | $8.76 | 0 | 61 | |
| Marriott Tina | President and COO | 535457 0.3073% | $8.76 | 0 | 26 | |
| Li Dean Y | director | 421000 0.195% | $8.76 | 0 | 4 | |
| Virani Shafique | Chief Business Officer | 136748 0.0633% | $8.76 | 0 | 26 | |
| Burrell Terry-Ann | director | 54847 0.0254% | $8.76 | 0 | 2 | |
| Dar Zavain | director | 53823 0.0249% | $8.76 | 0 | 1 | |
| Mubadala Investment Co PJSC | 10 percent owner | 12985927 6.0152% | $8.76 | 42 | 0 | +0.28% |
| Lux Ventures IV, L.P. | 10 percent owner | 100000 0.0463% | $8.76 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| ARK Investment Management LLC | $245.14M | 10.35 | 24.59M | +19.04% | +$39.21M | 1.71 | |
| Baillie Gifford Co | $239.96M | 10.13 | 24.07M | -0.46% | -$1.11M | 0.19 | |
| The Vanguard Group | $159.67M | 6.74 | 16.01M | +2.23% | +$3.49M | <0.01 | |
| BlackRock | $122.84M | 5.18 | 12.32M | -0.59% | -$726,184.90 | <0.01 | |
| Kinnevik Ab Publ | $103.74M | 4.38 | 10.41M | 0% | +$0 | 100 | |
| Nikko Asset Management Americas Inc | $103.11M | 4.36 | 10.36M | +12.59% | +$11.53M | 0.98 | |
| Sumitomo Mitsui Trust Holdings | $103.32M | 4.36 | 10.36M | +12.59% | +$11.56M | 0.07 | |
| State Street | $103.21M | 4.36 | 10.35M | -14.81% | -$17.94M | <0.01 | |
| Fidelity Investments | $92.33M | 3.9 | 9.26M | -15.02% | -$16.32M | 0.01 | |
| Mic Capital Management Uk Llp | $84.26M | 3.56 | 8.45M | 0% | +$0 | 16.01 | |
| NVIDIA | $76.83M | 3.24 | 7.71M | 0% | +$0 | 23.09 | |
| Data Collective Iv Gp Llc | $59.23M | 2.5 | 5.94M | 0% | +$0 | 51.36 | |
| Dcvc Opportunity Fund Ii Gp Llc | $39.39M | 1.66 | 3.95M | 0% | +$0 | 55.14 | |
| Geode Capital Management | $34.41M | 1.45 | 3.45M | +3.76% | +$1.25M | <0.01 | |
| EXOR INVESTMENTS (UK) LLP | $21.69M | 0.92 | 2.18M | +16% | +$2.99M | 0.91 | |
| Dimensional Fund Advisors | $20.89M | 0.88 | 2.1M | -1.97% | -$419,836.70 | 0.01 | |
| Morgan Stanley | $19.58M | 0.83 | 1.96M | -23.76% | -$6.1M | <0.01 | |
| Credit Suisse | $19.31M | 0.82 | 1.94M | +13.8% | +$2.34M | 0.02 | |
| PLATINUM INVESTMENT MANAGEMENT LTD | $17.95M | 0.76 | 1.8M | -20.82% | -$4.72M | 0.24 | |
| Bank of America | $16.98M | 0.72 | 1.7M | +116.86% | +$9.15M | <0.01 | |
| Northern Trust | $12.83M | 0.54 | 1.29M | -0.69% | -$88,703.09 | <0.01 | |
| Charles Schwab | $12.09M | 0.51 | 1.21M | +1.86% | +$220,636.11 | <0.01 | |
| JPMorgan Chase | $10.79M | 0.46 | 1.08M | +184.16% | +$6.99M | <0.01 | |
| Comprehensive Financial Management LLC | $9.39M | 0.4 | 941,895 | 0% | +$0 | 0.3 | |
| Laurion Capital Management LP | $9.05M | 0.38 | 907,616 | 0% | +$0 | 0.25 | |
| Vestmark Advisory Solutions Inc | $8.97M | 0.38 | 900,019 | +90.58% | +$4.26M | 0.52 | |
| Two Sigma | $8.94M | 0.38 | 896,480 | +68.31% | +$3.63M | 0.02 | |
| Goldman Sachs | $8.94M | 0.38 | 897,020 | -24.73% | -$2.94M | <0.01 | |
| Rafferty Asset Management Llc | $8.88M | 0.38 | 890,239 | -18.34% | -$1.99M | 0.03 | |
| BNY Mellon | $8.79M | 0.37 | 881,810 | +5.83% | +$483,893.80 | <0.01 | |
| Susquehanna International Group | $8.31M | 0.35 | 833,872 | +128.96% | +$4.68M | 0.01 | |
| Citigroup | $7.99M | 0.34 | 801,187 | +97.9% | +$3.95M | 0.01 | |
| Nuveen | $7.95M | 0.34 | 796,902 | +43.09% | +$2.39M | <0.01 | |
| Liontrust Investment Partners LLP | $7.48M | 0.32 | 750,000 | +45.63% | +$2.34M | 0.11 | |
| Cercano Management Llc | $6.83M | 0.29 | 685,018 | 0% | +$0 | 0.19 | |
| UBS | $6.7M | 0.28 | 672,431 | -2.81% | -$194,215.60 | <0.01 | |
| Voloridge Investment Management, LLC | $6.59M | 0.28 | 660,969 | +12.99% | +$757,859.59 | 0.02 | |
| Institute For Wealth Management Llc | $5.79M | 0.25 | 581,149 | New | +$5.79M | 0.79 | |
| Bellevue Group | $4.24M | 0.18 | 425,249 | +143.62% | +$2.5M | 0.07 | |
| Point72 Asset Management | $3.99M | 0.17 | 400,700 | -72.75% | -$10.66M | 0.01 | |
| Ensign Peak Advisors Inc | $3.98M | 0.17 | 398,936 | +2.95% | +$113,867.37 | 0.01 | |
| Marshall Wace | $3.9M | 0.17 | 391,518 | New | +$3.9M | 0.01 | |
| First Trust | $3.77M | 0.16 | 377,725 | +49.48% | +$1.25M | <0.01 | |
| Citadel Advisors LLC | $3.39M | 0.14 | 340,374 | +832.68% | +$3.03M | <0.01 | |
| OZ MANAGEMENT LLC | $3.17M | 0.13 | 318,400 | New | +$3.17M | 0.05 | |
| Barclays | $3.13M | 0.13 | 314,301 | -47.31% | -$2.81M | <0.01 | |
| Twinbeech Capital Lp | $3.13M | 0.13 | 313,487 | New | +$3.13M | 0.06 | |
| Swiss National Bank | $3.08M | 0.13 | 308,500 | +9.63% | +$270,187.00 | <0.01 | |
| LAZARD ASSET MANAGEMENT LLC | $2.8M | 0.12 | 280,668 | -24.49% | -$907,494.76 | <0.01 | |
| Natixis | $2.72M | 0.12 | 272,598 | New | +$2.72M | 0.02 |